We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer

By LabMedica International staff writers
Posted on 20 Apr 2026

Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. More...

Identifying molecular drivers that tip tumors toward invasion and metastasis remains a clinical priority, and understanding how epidermal identity is maintained may help flag high-risk disease earlier. New findings now identify a protein safeguard that preserves epithelial programming and limits the transition to metastatic behavior.

Hebrew University of Jerusalem researchers identified WWOX as a molecular “protein shield” that preserves epithelial identity in cSCC. The study outlines how this protein functions as a primary defense against progression to aggressive disease. Loss of WWOX was linked to transformation of common skin cancer cells into invasive, poorly differentiated forms.

Mechanistically, WWOX stabilizes the p63 protein, a master regulator that maintains epithelial structure and function. When WWOX is intact, p63 remains stable and skin cells retain their identity. When WWOX is lost, p63 levels drop, triggering epithelial‑to‑mesenchymal transition (EMT) that endows cells with migratory properties, enabling invasion and dissemination to the lungs and other organs.

Using advanced genetic models alongside human tissue samples, the investigators showed that combined loss of WWOX and the tumor suppressor p53 markedly accelerated tumor onset. Tumors arising under double deficiency were earlier, more aggressive, and poorly differentiated compared with settings in which WWOX remained functional. In these models, 100% of subjects with dual WWOX–p53 loss developed tumors, versus a much lower percentage in control groups.

Analyses of human tissue microarrays supported the translational relevance: as cSCC advanced, WWOX and p63 levels declined in tandem. According to the authors, this correlation suggests both proteins could serve as clinical biomarkers to help predict which tumors are likely to become dangerous. The findings were published in Proceedings of the National Academy of Sciences under the title “WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.” The results further suggest that restoring WWOX, stabilizing p63, or promoting epithelial differentiation might inhibit EMT and slow tumor growth.

Related Links
Hebrew University of Jerusalem


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Portable POCT Blood Gas Analyzer
BD100
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.